GILEAD SCIENCES INC's ticker is GILD and the CUSIP is 375558103. A total of 1,684 filers reported holding GILEAD SCIENCES INC in Q2 2023. The put-call ratio across all filers is 0.78 and the average weighting 0.3%.
About GILEAD SCIENCES INC
Gilead Sciences Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative medicines. The company is headquartered in Foster City, California, and has operations in North America, Europe, and Asia.
Gilead Sciences has a strong portfolio of products that address some of the most pressing medical needs in the world. The company's products are used to treat a range of diseases, including HIV/AIDS, hepatitis B and C, cancer, and respiratory and cardiovascular diseases.
One of the company's most successful products is Truvada, a medication used to prevent the transmission of HIV. Truvada has been a game-changer in the fight against HIV/AIDS, and has helped to significantly reduce the number of new infections in high-risk populations.
Gilead Sciences has also been at the forefront of the fight against COVID-19. The company's antiviral drug, remdesivir, has been approved by the FDA for the treatment of COVID-19 in hospitalized patients. Remdesivir has been shown to reduce the length of hospital stays for COVID-19 patients, and has been hailed as a major breakthrough in the fight against the pandemic.
Overall, Gilead Sciences is a company that is making a real difference in the world of medicine. With a strong portfolio of products and a commitment to innovation, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $723 | -99.9% | 10,586 | -4.1% | 0.06% | -21.3% |
| Q1 2024 | $808,500 | -30.0% | 11,039 | -22.6% | 0.08% | -14.8% |
| Q4 2023 | $1,155,414 | +16.2% | 14,263 | +7.4% | 0.09% | -48.8% |
| Q3 2023 | $994,710 | +120617.2% | 13,275 | -15.0% | 0.17% | +135.6% |
| Q2 2023 | $824 | -1.9% | 15,626 | +54.4% | 0.07% | +7.4% |
| Q1 2023 | $840 | -100.0% | 10,122 | -34.2% | 0.07% | -41.4% |
| Q4 2022 | $1,321,425,453 | +184199.2% | 15,392 | +32.3% | 0.12% | +65.7% |
| Q3 2022 | $717,000 | +143.1% | 11,631 | +143.8% | 0.07% | +133.3% |
| Q2 2022 | $295,000 | +27.2% | 4,771 | +22.2% | 0.03% | +57.9% |
| Q1 2022 | $232,000 | -2.9% | 3,904 | +18.3% | 0.02% | -5.0% |
| Q4 2021 | $239,000 | +4.4% | 3,300 | +0.7% | 0.02% | -20.0% |
| Q3 2021 | $229,000 | -5.4% | 3,278 | +4.4% | 0.02% | -40.5% |
| Q2 2020 | $242,000 | -75.0% | 3,141 | -75.5% | 0.04% | -86.9% |
| Q1 2018 | $968,000 | -1.3% | 12,836 | -6.2% | 0.32% | +0.6% |
| Q4 2017 | $981,000 | -17.4% | 13,688 | -6.6% | 0.32% | -32.6% |
| Q3 2017 | $1,187,000 | +78.2% | 14,649 | +55.6% | 0.47% | +55.6% |
| Q2 2017 | $666,000 | +17.9% | 9,416 | +13.1% | 0.30% | +23.6% |
| Q1 2017 | $565,000 | -7.5% | 8,323 | -2.5% | 0.25% | -12.8% |
| Q4 2016 | $611,000 | – | 8,538 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DOMINI IMPACT INVESTMENTS LLC | 4,906 | $388,000 | 17.99% |
| Cabot-Wellington, LLC | 147,130 | $11,641,000 | 9.41% |
| Hollow Brook Wealth Management LLC | 190,499 | $15,072,000 | 8.91% |
| Temasek Holdings (Private) Ltd | 13,830,516 | $1,094,270,000 | 8.86% |
| Passport Capital, LLC | 5,000,000 | $395,600,000 | 8.19% |
| Tekla Capital Management LLC | 2,660,131 | $210,470,000 | 8.09% |
| BB BIOTECH AG | 2,774,596 | $219,526,000 | 7.72% |
| Gabalex Capital Management LLC | 275,000 | $21,758,000 | 7.62% |
| NORTH TIDE CAPITAL, LLC | 800,000 | $63,296,000 | 6.89% |
| MUHLENKAMP & CO INC | 214,495 | $16,971,000 | 6.41% |